EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing Rilmenidine as a Potential Antimetastatic Therapy Targeting Nischarin in Pancreatic Ductal Adenocarcinoma

Kristina Živić, Marijana Pavlović iD, Marija Ostojić iD, Danijel Galun iD, Aleksandar Pavić, Tatjana Srdić-Rajić iD, Jelena Grahovac iD

Cells · 03.06.2026 · 15 (11) · 1032

DOI: 10.3390/cells15111032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 03.06.2026. Verfasst von Kristina Živić und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Drug Repositioning, Rilmenidine. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Fund of the Republic of Serbia, Ministry of Science, Technological Development, and Innovation, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancer types with a dismal prognosis, where early metastatic dissemination and rich desmoplastic stroma limit the therapeutic efficacy. Nischarin (NISCH)/Imidazoline-1 receptor (IR-1) is a potential tumor suppressor that is involved in the regulation of cell migration, invasion, and cytoskeletal organization. Importantly, several clinically approved agonists have been shown to target this receptor. This study aimed to examine NISCH expression in PDAC and the effects of its agonists with the intent of drug repurposing. NISCH was expressed in PDAC tumor tissue, in both the epithelial and stromal compartments of tumors, and higher NISCH expression was associated with longer patient survival. Out of the three tested NISCH agonists, moxonidine, clonidine and rilmenidine, rilmenidine was the only one affecting cancer cell viability and at high doses induced cancer cell apoptosis. Transcriptome analysis of rilmenidine-treated PDAC cells revealed changes associated with cytoskeletal organization, translating into decreased adhesion and migration in vitro. In cancer-associated fibroblasts (CAFs), rilmenidine treatment decreased the expression of activation markers and limited cancer cell-CAF cytokine communication in the co-culture. Ultimately, in the in vivo tumor xenograft zebrafish model, rilmenidine reduced the metastatic spread of pancreatic cancer cells. Our results suggest that the NISCH agonist rilmenidine is a promising candidate for drug repurposing as an antimetastatic agent in PDAC, and that NISCH can be a potential target for the development of new PDAC therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsDrug RepositioningRilmenidineImidazoline ReceptorsHumansAnimalsCell Line, TumorCell MovementZebrafishNeoplasm MetastasisGene Expression Regulation, NeoplasticApoptosisMale

Stichwörter der Autor:innen

drug repurposingmetastasisnischarinpancreatic cancerrilmenidine

Substanzen

RilmenidineImidazoline Receptors

Autor:innen und Institutionen

  • Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia.
  • School of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
  • HPB Unit, Clinic for Digestive Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
  • Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11000 Belgrade, Serbia.

ORCID-Profile: Marijana Pavlović, Marija Ostojić, Danijel Galun, Tatjana Srdić-Rajić, Jelena Grahovac

Förderung

  • Science Fund of the Republic of Serbia
  • Ministry of Science, Technological Development, and Innovation
  • European Union
  • Ministry of Education, Science, and Technological Development of the Republic of Serbia Agreements
  • European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie

Zitieren

APA

Živić, K., Pavlović, M., Ostojić, M., Galun, D., Pavić, A., Srdić-Rajić, T., & Grahovac, J. (2026). Repurposing Rilmenidine as a Potential Antimetastatic Therapy Targeting Nischarin in Pancreatic Ductal Adenocarcinoma. Cells, 15(11), 1032. https://doi.org/10.3390/cells15111032

Vancouver

Živić K, Pavlović M, Ostojić M, Galun D, Pavić A, Srdić-Rajić T, et al. Repurposing Rilmenidine as a Potential Antimetastatic Therapy Targeting Nischarin in Pancreatic Ductal Adenocarcinoma. Cells. 2026;15(11):1032. doi:10.3390/cells15111032

BibTeX
@article{ivi2026,
  author = {Živić, Kristina and Pavlović, Marijana and Ostojić, Marija and Galun, Danijel and Pavić, Aleksandar and Srdić-Rajić, Tatjana and Grahovac, Jelena},
  title = {Repurposing Rilmenidine as a Potential Antimetastatic Therapy Targeting Nischarin in Pancreatic Ductal Adenocarcinoma},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {11},
  pages = {1032},
  doi = {10.3390/cells15111032}
}
Kostenlos starten →